PLX (Protalix BioTherapeutics, Inc. Common Stock) Stock Analysis - News
Protalix BioTherapeutics, Inc. Common Stock (PLX) is a publicly traded Healthcare sector company. As of May 21, 2026, PLX trades at $1.94 with a market cap of $153.89M and a P/E ratio of 10.07. PLX moved +5.53% today. Year to date, PLX is +12.29%; over the trailing twelve months it is +16.86%. Its 52-week range spans $0.99 to $3.19. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces PLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in PLX news today?
Protalix Extends Cash Runway into Late 2027, Completes Phase III Enrollment: Protalix said its cash and liquid assets are sufficient to fund operations into late 2027 and reported a year-over-year decrease in Q1 2026 operating expenses. Management also confirmed full enrollment in its pivotal Phase III pegunigalsidase alfa trial.
Protalix Extends Cash Runway into Late 2027, Completes Phase III Enrollment: Protalix said its cash and liquid assets are sufficient to fund operations into late 2027 and reported a year-over-year decrease in Q1 2026 operating expenses. Management also confirmed full enrollment in its pivotal Phase III pegunigalsidase alfa trial.
Does Rallies summarize PLX news?
Yes. Rallies summarizes PLX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is PLX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PLX. It does not provide personalized investment advice.
